bimagrumab glp-1 A phase 2 clinical trial has demonstrated that bimagrumab, when combined with semaglutide, resulted in significant weight loss for trial participants while maintaining lean muscle mass – suggesting a promising approach for What's Next After GLP-1? ActRII

CrossRef Retroperitoneal malignant schwannoma in a child Jun Wang, Mingming Yu, Haobo Zhu, Liqu Huang, Xiaojiang Zhu, Chenjun Chen, Yaqi Shi, Geng Ma, Yunfei Guo, Zhongqin Yu Journal of International Medical Research.2018

Duration of intervention was 12, 26, 40 and 52 weeks in one, one, three and two studies, respectively

it's about fundamentally altering the body's metabolic engine

Oral and topical forms of GSH have shown moderate success in reducing melanin levels with minimal side effects, while intravenous use, though popular, raises significant safety concerns, including risks of anaphylaxis and liver damage

Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives